- FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
- Semaglutide: Potential Breakthrough in Addiction Treatment for Alcohol
- Fatty Acids in Beef and Dairy Enhance Immune Cell Cancer Response
- Pancreatic Cancer Triggers Immune Response Contradicting Previous Views
- Scientists Unveil Children’s Innate Weapon Against COVID-19
- New Zealand Government Plans to Repeal Strict Smoking Ban
U.S. begins COVID-19 vaccination
U.S. begins COVID-19 vaccination. The United States launched the COVID-19 vaccination on the 14th. The first group of people to be vaccinated is medical staff and groups living in long-term care institutions such as nursing homes.
In the morning, Sandra Lindsay, a nurse in the intensive care unit of the Long Island Jewish Medical Center in New York, was the first to be vaccinated, becoming the first vaccinator in New York State and one of the first vaccinators in the United States.
During the live video vaccination, Lindsay expressed her gratitude to all front-line workers of the epidemic and people around the world who have made unremitting efforts to fight the epidemic. She said that she “feeled hope” today and was relieved, hoping that vaccination would “be the beginning of ending this very painful period in American history.”
New York State Governor Andrew Cuomo said on the same day that this was the light at the end of the tunnel, “but it is a very long tunnel.”
On the 11th, the US Food and Drug Administration approved an emergency use authorization application for the COVID-19 vaccine jointly developed by Pfizer Pharmaceuticals Co., Ltd. and German Biotech. This is the first new coronavirus vaccine approved for emergency use in the United States, and is allowed to be used for people 16 years and older.
Robert Redfield, director of the US Centers for Disease Control and Prevention, signed a proposal to use this vaccine on the 13th. He said in a statement that the first batch of vaccinations is scheduled to start on the 14th, which is a further effort to protect the American people, slow the impact of the epidemic, and restore people’s lives and the normal state of the country.
The COVID-19 vaccine jointly developed by Pfizer Pharmaceuticals and German Biotech is a messenger ribonucleic acid (mRNA) vaccine that can target the spike protein of the new coronavirus. The interim analysis data of the phase III clinical trials released by the two companies in November showed that the vaccine’s effectiveness exceeded 90%. The two companies said it will take another two years to continue collecting data on the effectiveness and safety of this vaccine. This vaccine needs to be stored in an environment of minus 70 degrees Celsius